Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTCH1 | P46531 | 5/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 1/20 | 1.00 |
| ▸ | CDK2 | P24941 | 1/20 | 1.00 |
| ▸ | PSEN1 | P49768 | 1/20 | 1.00 |
| ▸ | PSEN2 | P49810 | 1/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 1/20 | 1.00 |
| ▸ | APH1B | Q8WW43 | 1/20 | 1.00 |
| ▸ | NCSTN | Q92542 | 1/20 | 1.00 |
| ▸ | APH1A | Q96BI3 | 1/20 | 1.00 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 14/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.66 |
| ▸ | TSHR | P16473 | 4/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 5/20 | 0.54 |
| ▸ | CASP1 | P29466 | 3/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19676387 | 1.00 | NOTCH1 (1.00) | NOTCH1CCNA2CDK2PSEN1PSEN2 | |
| SCHEMBL16854538 | 0.89 | NOTCH1 (0.81) | NOTCH1CCNA2CDK2PSEN1PSEN2 | |
| SCHEMBL16854567 | 0.89 | NOTCH1 (0.81) | NOTCH1CCNA2CDK2PSEN1PSEN2 | |
| SCHEMBL15538182 | 0.89 | NOTCH1 (0.79) | NOTCH1CCNA2CDK2PSEN1PSEN2 | |
| SCHEMBL16854539 | 0.88 | NOTCH1 (0.79) | NOTCH1CCNA2CDK2PSEN1PSEN2 | |
| SCHEMBL3325137 | 0.87 | NOTCH1 (0.76) | NOTCH1CCNA2CDK2PSEN1PSEN2 | |
| SCHEMBL19366382 | 0.86 | NOTCH1 (0.75) | NOTCH1CCNA2CDK2PSEN1PSEN2 | |
| SCHEMBL16854540 | 0.86 | NOTCH1 (0.75) | NOTCH1CCNA2CDK2PSEN1PSEN2 | |
| SCHEMBL16850575 | 0.86 | NOTCH1 (0.75) | NOTCH1CCNA2CDK2PSEN1PSEN2 | |
| SCHEMBL15537264 | 0.86 | NOTCH1 (0.80) | NOTCH1CCNA2CDK2PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4720261-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | University of Southern California (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4684836-A2 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | Oryzon Genomics, S.A. (ES) | 2026-01-28 | — | — | EP | claimed |
| US-20250304916-A1 | METHODS AND COMPOSITIONS FOR GENERATING VASCULAR LEPTOMENINGEAL CELLS | TRAILHEAD BIOSYSTEMS INC (US) | 2025-10-02 | — | — | US | claimed |
| US-20250213585-A1 | COMPOSITIONS AND METHODS OF A CONCOMITANT THERAPY OF ALTERNATING ELECTRIC FIELDS AND NOTCH-1 INHIBITOR | SHANGHAI INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY (CN) | 2025-07-03 | — | — | US | claimed |
| EP-4577639-A1 | METHODS AND COMPOSITIONS FOR SMALL MOLECULE BASED PANCREATIC BETA CELL INDUCTION | Trailhead Biosystems Inc. (US) | 2025-07-02 | — | — | EP | claimed |
| US-20250092360-A1 | METHODS AND COMPOSITIONS FOR GENERATING SOMATOSTATIN+ INTERNEURONS FROM HUMAN FOREBRAIN NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2025-03-20 | — | — | US | claimed |
| CN-119162082-A | Method for preparing extrahepatic vesicles/apoptotic vesicles by inducing fibroblasts to be directly reprogrammed into liver-like cells and application of method | 中国人民解放军海军军医大学 | 2024-12-20 | — | — | CN | claimed |
| CN-114096557-B | Production of dorsal foregut and anterior endoderm cells | 克利夫兰诊所基金会 | 2024-12-13 | — | — | CN | claimed |
| WO-2024243567-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-11-28 | — | — | WO | claimed |
| WO-2024044268-A1 | METHODS AND COMPOSITIONS FOR SMALL MOLECULE BASED PANCREATIC BETA CELL INDUCTION | TRAILHEAD BIOSYSTEMS INC. (US) | 2024-02-29 | — | — | WO | claimed |
| CN-112961823-B | Culture solution for preparing islet beta cells by inducing directional differentiation of pluripotent stem cells | 上海爱萨尔生物科技有限公司 | 2024-01-23 | — | — | CN | claimed |
| US-11850273-B2 | Chemical reprogramming of human glial cells into neurons for brain and spinal cord repair | THE PENN STATE RESEARCH FOUNDATION (US) | 2023-12-26 | — | — | US | claimed |
| CN-117025537-A | Special culture solution for small cell lung cancer organoids and application thereof | 福州大学 | 2023-11-10 | — | — | CN | claimed |
| US-20230332103-A1 | Methods and Compositions for Generating Human Forebrain Neural Progenitor Cells and for Maturation Thereof to Parvalbumin+ Interneurons | TRAILHEAD BIOSYSTEMS INC. | 2023-10-19 | — | — | US | claimed |
| WO-2023075913-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN FOREBRAIN NEURAL PROGENITOR CELLS AND FOR MATURATION THEREOF TO PARVALBUMIN+ INTERNEURONS | TRAILHEAD BIOSYSTEMS INC. (US) | 2023-05-04 | — | — | WO | claimed |
| CN-109251894-B | Chemical reprogramming of human glial cells into neural cells for brain and spinal cord repair | 宾州研究基金会 | 2022-10-04 | — | — | CN | claimed |
| US-20220220447-A1 | GENERATING DORSAL FOREGUT, AND ANTERIOR DOMAIN, ENDODERM CELLS | THE CLEVELAND CLINIC FOUNDATION | 2022-07-14 | — | — | US | claimed |
| EP-3972990-A1 | GENERATING DORSAL FOREGUT, AND ANTERIOR DOMAIN, ENDODERM CELLS | The Cleveland Clinic Foundation (US) | 2022-03-30 | — | — | EP | claimed |
| CN-114096557-A | Generation of germ layer cells in the dorsal foregut and anterior structural domains | 克利夫兰诊所基金会 | 2022-02-25 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11850273-B2 | Chemical reprogramming of human glial cells into neurons for brain and spinal cord repair | BMP4, GSK3B, PYGB | NOTCH1 20/4885CCNA2 3329/4885CDK2 457/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | NOTCH1 350/4885CCNA2 1609/4885CDK2 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.